Fistula formation is the most common complication of perianal Crohn's disease (CD) and occurs in about 33% of patients with CD after ten years of active disease. A multi-disciplinary approach consisting of control of the perianal sepsis with drainage and setons, and treatment of the inflammation with biologics and immunomodulators is the initial approach. Surgical management of these often complex fistulae can involve a multitude of interventions, all of which require adequate control of the inflammatory process to be successful. Risks of incontinence, nonhealing wound and the developement of malignancy make surgical managemnt especially challenging.
This session is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Learning Objectives:
Assess the risks associated with CDI infection and recurrence in patients with IBD and the barriers to timely identification and optimal treatment
Describe the most recent clinical data associated with current and emerging therapies for CDI
Evaluate the differences among the most current clinical guidelines and strategies for the optimal management of initial and recurrent CDI in patients with IBD